Navigation Links
FDA Advisers Endorse New Lupus Drug

By Steven Reinberg
HealthDay Reporter

TUESDAY, Nov. 16 (HealthDay News) -- U.S. Food and Drug Administration advisers voted 13-2 Tuesday to recommend approval of the first new drug in more than 50 years to treat the autoimmune disease lupus.

The drug, belimumab (Benlysta), is a so-called monoclonal antibody drug developed to treat patients who suffer from systemic lupus erythematosus.

Lupus is an autoimmune disease in which the body produces antibodies that attack and destroy healthy tissue. This can damage joints, skin, blood vessels and organs. Benlysta works by inhibiting the production of these antibodies.

While the FDA is not bound by its advisory committees' recommendations, it usually follows them.

Benlysta is made by Human Genome Sciences and GlaxoSmithKline.

In a report submitted to the advisory committee before the vote, the FDA had expressed some concerns about the efficacy and safety of the drug.

But other experts expressed optimism about the drug's worth.

"I really do think the drug is efficacious," said Sandra C. Raymond, president & CEO of the Lupus Foundation of America, who attended the advisory panel meeting. "What I'm hearing in terms of efficacy is pretty strong."

In a statement commenting on the panel's vote, Margaret Dowd, president and CEO of the Lupus Research Institute, said that, "we couldn't be more pleased. It's a historic day for the lupus community."

The FDA said it wanted the advisory panel to look at both the efficacy data, which according to the agency was modest, and the safety data, which the agency believed raised some serious issues. Specifically, the drug has been linked to depression and suicide.

Raymond noted, however, that many patients with lupus suffer from depression. And many patients in clinical trials testing the drug were also taking antidepressants, she added.

The advisory committee actually took three votes Tuesday. The other two votes endorsed the safety and the effectiveness of the drug.

The agency said it based its concerns on the results of two phase 3 trials that compared Benlysta with a placebo.

"The risks associated with belimumab include infection, malignancy, suicidality and overall number of deaths with a numerical imbalance that favored placebo treatment over belimumab treatment," according to the FDA paper filed before the vote.

Safety is important, Raymond said, but the drugs used to treat lupus now carry some significant side effects, too. "The safety of some of our medications is not good," she said. "So what are we comparing it to?"

The current treatments include chemotherapy and steroids, which can leave the door open to infections, cancers and other unwanted consequences, Raymond said.

Dr. Joan Merrill, head of clinical pharmacology at the Oklahoma Medical Research Foundation and medical director of the Lupus Foundation of America, added that "the safety data on Benlysta looks better than we usually see with biologics."

"We have to keep in mind that there is a natural ceiling on the percentage of patients who can respond to any targeted treatment. We do not yet know exactly how good Benlysta is," Merrill said.

What is known is that Benlysta was shown to be statistically superior to a placebo in two phase 3 trials, she said.

"I hope that the FDA will be able to approve it, after they complete the serious deliberations that they must make on all the data," Merrill said.

Another expert agreed.

"I am hoping the advisory committee will recommend approval of Benlysta, because it has been associated with statistically significant improvement in the response to treatment in two well-designed randomized, prospective, placebo-controlled trials studying different populations of people with systemic lupus," said Dr. Bevra H. Hahn, chief of rheumatology at UCLA's David Geffen School of Medicine.

"Very important are the observations that fatigue [a major complaint of almost everyone with lupus] and physical function improved significantly," she added.

More information

To learn more about lupus, visit the Lupus Foundation of America.

SOURCES: Sandra C. Raymond, president & CEO, Lupus Foundation of America; Joan Merrill, M.D., head, Clinical Pharmacology, Oklahoma Medical Research Foundation, Medical Director, Lupus Foundation of America; Bevra H. Hahn, M.D., professor, medicine, and chief, rheumatology, David Geffen School of Medicine, University of California, Los Angeles; Nov. 16, 2010, statement, Lupus Research Institute

Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. FDA Advisers Urge Stricter Regulation of Tanning Beds
2. FDA to Broaden Disclosure on Advisers Conflicts of Interest
3. FDA Advisers Say Avastin Shouldnt Be Used for Breast Cancer
4. FDA Advisers Divided on Whether to Ban Diet Drug Meridia
5. FDA Advisers Weigh Approval of Genetically Modified Salmon
6. FDA Advisers Consider Approval of Genetically Modified Salmon
7. FDA Advisers Back Anemia Drugs for Kidney Patients
8. FDA Advisers Consider New Lupus Drug
9. Health & Sports: Former NBA Star John Salley Endorses STEMTech Stem Cell Nutrition Products
10. Rep. Fattah Endorses Obama Health Care Bill, Refuses to Disarm in Procedural Dispute
11. GateWay Community College Receives Strong Endorsement for Re-accreditation
Post Your Comments:
Related Image:
FDA Advisers Endorse New Lupus Drug
(Date:6/27/2016)... ... June 27, 2016 , ... ... industry today announced its strategic partnership with Connance, a healthcare industry leader ... two companies’ proven, proprietary technology combine to provide health systems, hospitals and ...
(Date:6/26/2016)... ... June 26, 2016 , ... Pixel Film Studios Released ProSlice Levels, a Media ... give their videos a whole new perspective by using the title layers in ... Studios. , ProSlice Levels contains over 30 Different presets to choose from. ...
(Date:6/25/2016)... Austin, TX (PRWEB) , ... June 25, 2016 , ... ... Fellow of the American College of Mohs Surgery and to Dr. Russell Peckham for ... popular and highly effective treatment for skin cancer. The selective fellowship in Mohs Micrographic ...
(Date:6/25/2016)... Oklahoma (PRWEB) , ... June 25, 2016 , ... ... both athletes and non-athletes recover from injury. Recently, he has implemented orthobiologic procedures ... Oklahoma City area —Johnson is one of the first doctors to perform the ...
(Date:6/24/2016)... ... June 24, 2016 , ... June 19, 2016 is World Sickle ... chronic pain and the benefits of holistic treatments, Serenity Recovery Center of ... Sickle Cell Disease. , Sickle Cell Disease (SCD) is a disorder of the red ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... -- VMS Rehab Systems, Inc. ( ) reported today ... to build a strong and stable market for trading ... the OTC Markets-pink current trading platform. Explains ... seeing an anomaly in market trading activities that may ... Company, but shareholders and market players as well. I ...
(Date:6/24/2016)... 2016  Consumers have taken a more active ... more emphasis on patient outcomes. ... the pharmaceutical industry have evolved beyond just providing ... are focusing on becoming more patient-oriented across their ... services that improve health. ...
(Date:6/24/2016)... SOUTH SAN FRANCISCO, Calif. , June 24, ... GBT ), a biopharmaceutical company developing novel ... with significant unmet needs, today announced the closing ... 6,400,000 shares of common stock, at the public ... the shares in the offering were offered by ...
Breaking Medicine Technology: